3,4-Methylenedioxyphentermine
Names | |
---|---|
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-2-methylpropan-2-amine | |
Other names
MDP; MDPH; 3,4-Methylenedioxyphentermine;
3,4-Methylenedioxy-alpha,alpha-dimethyl-1-ethane | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C11H15NO2 | |
Molar mass | 193.246 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
3,4-Methylenedioxyphentermine (MDPH) is a lesser-known drug of the amphetamine family. MDPH was first synthesized by Alexander Shulgin. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPH.
In his book PiHKAL (Phenethylamines i Have Known And Loved), the dosage range is listed as 160–240 mg, and the duration as 3–5 hours.[1] MDPH's effects are very similar to those of MDA: they both are smooth and "stoning," and do not cause any visuals. They also alter dreams and dream patterns. Shulgin describes MDPH as a promoter; it promotes the effects of other drugs, similarly to 2C-D.
The N-methyl derivative, 3,4-methylenedioxy-N-methylphentermine (MDMPH), has been described by Shulgin as lacking MDMA-like effects.[2] Accordingly, MDMPH, as well as MDPH, were found to be inactive as serotonin releasing agents in vitro.[2][3]
Legality
[edit]United Kingdom
[edit]This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[4]
See also
[edit]- 3,4-Dichloroamphetamine
- Cericlamine
- Chlorphentermine
- Cloforex
- Clortermine
- Etolorex
- Methylenedioxyphenmetrazine
- Phentermine
References
[edit]- ^ MDPH entry in PiHKAL
- ^ a b Nichols, David F.; Oberlender, Robert (1990). "Structure-Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Agents?". Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Vol. 9. Boston, MA: Springer US. p. 105–131. doi:10.1007/978-1-4613-1485-1_7. ISBN 978-1-4612-8799-5.
- ^ Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GK (May 1982). "Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes". J Med Chem. 25 (5): 530–535. doi:10.1021/jm00347a010. PMID 7086839.
- ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.